Conference Day 2
8.00 Coffee Room Opens
8:50 am Chair’s Opening Remarks
How Will the Plethora of Anti-BCMA’s Be Differentiated?
9:00 am Panel Discussion:: The Differentiating Debate: On-The-Shelf vs Off-The Shelf
Synopsis
- Dissecting the current state of accessibility
- What roles separate antibody-based and cell-based therapies – can they all live together?
- Discussing manufacturing production capabilities and scaling predictions for CAR-T: academic centers and community hospitals
- Exploring pricing: can profitability be demonstrated?
- Europe vs US vs global
- Understanding age group considerations
- How can we ensure timely CAR-T slot availability for patients in need? (Future of off-the shelf CAR-T’s or manufacturing changes?)
- What clinical timelines are predicted: combinations, lines of therapy? What is the end goal?
- How can we contextualize this in the competitive landscape? Competitive differentiation?
9:30 am Teclistamab (BCMAxCD3) Journey from Discovery to Filing
Synopsis
- Telling the story of a BCMA-targeted drug developmental success from bench to bedside
- Exploring the latest exciting data and predicting gaps and future directions for space
10:00 am Correlates of Durable Response to Ide-Cel from the KarMMa Study
Synopsis
- Exploring baseline patient and tumor features associated with durable response
- Understanding correlates of overall and complete response
- Post-infusion correlates of more durable response
10.30 Morning Refreshments & Poster Session
11:30 am Zevor-cel (CT053) BCMA CAR-T Cells in Multiple Myeloma
Synopsis
- Reporting the safety and efficacy of zevor-cel CAR-BCMA T cells (CT053) utilizing a newly identified, fully-human BCMA-specific scFv with fine-tuned binding affinity
- Zevor-cel showed low-level CD3 autophosphorylation and induced relatively lowlevel IL-6 secretion while displaying potent preclinical antitumor activities
- Sharing results from two registration studies (LUMMICAR-1 in China and LUMMICAR-2 in US and Canada)
12:00 pm ARC-sparX Platform Technology & Novel BCMA-Targeting Binding Domain for the Treatment of Patients with RRMM
Synopsis
- Exploring preclinical rationale, clinical trial results, and the next steps for CARTddBCMA as well as the next generation ARCsparX platform
12:30 pm Targeting Alternative T Cell Effector Pathways to Enhance the Anti-Tumor Activity of CD3-Engaging Bispecific Antibodies
Synopsis
– CD3-engaging bispecific antibodies drive potent anti-tumor activity in pre-clinical models as well as in patients
– However, not all patients respond to therapy and many relapse after initially responding
– Here, we describe novel therapeutics that engage alternative T cell signaling pathways and demonstrate combinatorial anti-tumor effects in high-bar pre-clinical models
1.00 Lunch Break
Combination Strategies & Sequencing of Therapies: Selecting Patients & Optimizing Trial Design
2:00 pm How to Select the Bi-Specific mAb For the Treatment of RRMM?
Synopsis
- Patient and disease-based factors should drive the treatment decision making
- Bi-specific mAbs are off the shelf-drugs that will present wide availability
- Bi-specific mAbs might be combined wih other mABs or IMiD’s to complement the treatment strategies and improve outcomes
2:30 pm Exploring the Rational & Optimal Combinations
Synopsis
- Standardizing care: should we be more upfront with targeted therapies?
- Exploring optimal ways to treat & overcome toxicities
- Utilizing pre-clinical models to understand drug combinations and sequence
- Sharing insights on the different hypothesis made for different combinations
- BCMA CAR-T relapse, what’s next?
3.00 Afternoon Refreshments
3:30 pm Gamma Secretase Inhibitors: Potentiating BCMA-Targeted Therapies
Synopsis
- Synergistic mechanism of action for gamma secretase inhibition on BCMA
applies to all BCMA-targeted therapy modalities - Sharing an open development approach by partnering across all BCMA modalities and also broadly within each modality
- GSI + BCMA combination synergy and potentiation as an example of translational medicine and precision medicine from proof-of-concept to validation with safety and efficacy evidence from clinical trials
4:00 pm Closing Panel Discussion: Future Directions for BCMA-Directed Therapies
Synopsis
- Pricing/Cost
- Accessibility changes
- Is improved trial design needed?
- How will they be commercialized?
- What is the ultimate limit of BCMA as a target for myeloma?
- How will cell therapy infrastructure evolve & how will this effect current situation?
- Potential limitations to BCMA and how other targets (FcRb5/FcR115, NC28, CS1, SIRH5) could fit in the future clinical landscape
- Long-term outlook